Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP914236.RATg9aJ-JlibHDMhC2GiZ5EQE2mv1z_rMb2mT8rsizSc4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP914236.RATg9aJ-JlibHDMhC2GiZ5EQE2mv1z_rMb2mT8rsizSc4130_assertion type Assertion NP914236.RATg9aJ-JlibHDMhC2GiZ5EQE2mv1z_rMb2mT8rsizSc4130_head.
- NP914236.RATg9aJ-JlibHDMhC2GiZ5EQE2mv1z_rMb2mT8rsizSc4130_assertion description "[Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP914236.RATg9aJ-JlibHDMhC2GiZ5EQE2mv1z_rMb2mT8rsizSc4130_provenance.
- NP914236.RATg9aJ-JlibHDMhC2GiZ5EQE2mv1z_rMb2mT8rsizSc4130_assertion evidence source_evidence_literature NP914236.RATg9aJ-JlibHDMhC2GiZ5EQE2mv1z_rMb2mT8rsizSc4130_provenance.
- NP914236.RATg9aJ-JlibHDMhC2GiZ5EQE2mv1z_rMb2mT8rsizSc4130_assertion SIO_000772 19855965 NP914236.RATg9aJ-JlibHDMhC2GiZ5EQE2mv1z_rMb2mT8rsizSc4130_provenance.
- NP914236.RATg9aJ-JlibHDMhC2GiZ5EQE2mv1z_rMb2mT8rsizSc4130_assertion wasDerivedFrom befree-20150227 NP914236.RATg9aJ-JlibHDMhC2GiZ5EQE2mv1z_rMb2mT8rsizSc4130_provenance.
- NP914236.RATg9aJ-JlibHDMhC2GiZ5EQE2mv1z_rMb2mT8rsizSc4130_assertion wasGeneratedBy ECO_0000203 NP914236.RATg9aJ-JlibHDMhC2GiZ5EQE2mv1z_rMb2mT8rsizSc4130_provenance.